SCHEMBL13781560

SCHEMBL13781560

Cc1sc(NC(=O)CCc2ccc(-c3ccccc3)cc2)c(C(=O)O)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HTT P42858 2/20 0.56
RECQL P46063 1/20 0.56
HPGD P15428 4/20 0.53
MAPT P10636 3/20 0.52
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KDM4E B2RXH2 3/20 0.51
HCAR2 Q8TDS4 7/20 0.50
CNR2 P34972 1/20 0.48
PKM P14618 2/20 0.47
FLT3 P36888 1/20 0.47
POLB P06746 1/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LTB4R Q15722 1/20 0.47
AIP O00170 1/20 0.47
SGTA O43765 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825129 0.92 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HTTRECQLHPGD
SCHEMBL13781600 0.85 HCAR2 (0.56) ALDH1A1SMN1; SMN2HTTRECQLHPGD
SCHEMBL13781563 0.81 HCAR2 (0.52) SMN1; SMN2HCAR2CNR2POLBLTB4R
SCHEMBL13781562 0.78 HCAR2 (0.58) ALDH1A1SMN1; SMN2HTTHPGDMAPT
SCHEMBL5275098 0.78 HCAR2 (0.56) HCAR2POLBLTB4R
SCHEMBL1800640 0.77 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2HTTHPGDMAPT
SCHEMBL5066827 0.74 HCAR2 (0.83) SMN1; SMN2HCAR2POLB
SCHEMBL13781559 0.74 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL7046207 0.72 HDAC1 (0.79)
SCHEMBL23413257 0.72 ALDH1A1 (0.83) ALDH1A1SMN1; SMN2HTTHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170891-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2009-07-02 US disclosed
US-20090170891-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2009-07-02 US disclosed
WO-2007120575-A2 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170891-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 ALDH1A1 1106/4885SMN1; SMN2 3840/4885HTT 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.